Health position paper and redox perspectives - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases.

Details

Ressource 1Download: 40059038.pdf (10706.50 [Ko])
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_57E1389C4D3F
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Health position paper and redox perspectives - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases.
Journal
Redox biology
Author(s)
Cuadrado A., Cazalla E., Bach A., Bathish B., Naidu S.D., DeNicola G.M., Dinkova-Kostova A.T., Fernández-Ginés R., Grochot-Przeczek A., Hayes J.D., Kensler T.W., León R., Liby K.T., López M.G., Manda G., Shivakumar A.K., Hakomäki H., Moerland J.A., Motohashi H., Rojo A.I., Sykiotis G.P., Taguchi K., Valverde Á.M., Yamamoto M., Levonen A.L.
ISSN
2213-2317 (Electronic)
ISSN-L
2213-2317
Publication state
Published
Issued date
04/2025
Peer-reviewed
Oui
Volume
81
Pages
103569
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Nuclear factor erythroid 2-related factor 2 (NRF2) is a redox-activated transcription factor regulating cellular defense against oxidative stress, thereby playing a pivotal role in maintaining cellular homeostasis. Its dysregulation is implicated in the progression of a wide array of human diseases, making NRF2 a compelling target for therapeutic interventions. However, challenges persist in drug discovery and safe targeting of NRF2, as unresolved questions remain especially regarding its context-specific role in diseases and off-target effects. This comprehensive review discusses the dualistic role of NRF2 in disease pathophysiology, covering its protective and/or destructive roles in autoimmune, respiratory, cardiovascular, and metabolic diseases, as well as diseases of the digestive system and cancer. Additionally, we also review the development of drugs that either activate or inhibit NRF2, discuss main barriers in translating NRF2-based therapies from bench to bedside, and consider the ways to monitor NRF2 activation in vivo.
Keywords
NF-E2-Related Factor 2/metabolism, Humans, Oxidation-Reduction, Noncommunicable Diseases/drug therapy, Oxidative Stress/drug effects, Animals, Neoplasms/metabolism, Neoplasms/drug therapy, Neoplasms/pathology, Drug repurposing, GSK-3, KEAP1, NRF2 diseasome, β-TrCP
Pubmed
Open Access
Yes
Create date
14/03/2025 16:54
Last modification date
25/03/2025 8:12
Usage data